In a phase I/II study involving 45 patients with previously treated NSCLC, treatment with subcutaneous azacytidine and the histone deacetylase (HDAC) inhibitor entinostat, the response rate was 4%.29 However, among the 19 patients that received subsequent therapy, four achieved major responses suggesting chemotherapy sensitisation. Here, HDAC9 is linked to non-small cell lung carcinoma.